May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
The Effect of the Dihydrobenzofuran Derivative on Lipid Hydroperoxide–Induced Rabbit Corneal Neovascularization
Author Affiliations & Notes
  • H. Ogura
    Ophthalmology,
    Showa University, Shinagawa–Ku, Japan
  • T. Nakanishi–Ueda
    Pharmacology,
    Showa University, Shinagawa–Ku, Japan
  • T. Ueda
    Ophthalmology,
    Showa University, Shinagawa–Ku, Japan
  • S. Uchida
    Pharmaceutical Laboratory, Odawara Research Center, Nippon Soda Co.Ltd.,, Odawara, Japan
  • N. Mochizuki
    Pharmaceutical Laboratory, Odawara Research Center, Nippon Soda Co.Ltd.,, Odawara, Japan
  • H. Yasuhara
    Pharmacology,
    Showa University, Shinagawa–Ku, Japan
  • D. Armstrong
    Ophthalmology,
    Showa University, Shinagawa–Ku, Japan
  • R. Koide
    Ophthalmology,
    Showa University, Shinagawa–Ku, Japan
  • Footnotes
    Commercial Relationships  H. Ogura, None; T. Nakanishi–Ueda, None; T. Ueda, None; S. Uchida, None; N. Mochizuki, None; H. Yasuhara, None; D. Armstrong, None; R. Koide, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4505. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Ogura, T. Nakanishi–Ueda, T. Ueda, S. Uchida, N. Mochizuki, H. Yasuhara, D. Armstrong, R. Koide; The Effect of the Dihydrobenzofuran Derivative on Lipid Hydroperoxide–Induced Rabbit Corneal Neovascularization . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4505.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effect of A–3922, dihydrobenzofuran derivative, on linoleic acid hydroperoxide(LHP)–induced corneal neovascularization in a rabbit model. Methods: Male New Zealand rabbits weighing 2.5–4 kg received 3 daily intraperitoneal injections of 10 and 30 mg/kg/day A–3922 dissolved in 1%NIKKOL HCO–60/DMSO=8/2, or buffer alone as control. One day after systemic equilibration, 10 µ L of LHP(40 mM) was injected with a 30 gauge needle into the corneal stroma of the superior quadrant 4.5 mm below the limbus. Maximum vessel length was measured by caliper and, photographs were taken for digital analysis with a surgical microscope at 1, 4, 7, 10, and 14 days after LHP injection. At sacrifice, vascular endothelial growth factor (VEGF) in the corneal tissue was measured by immunoassay kit(R &D system). Statistical analysis used multiple comparison (William’s). Results: At 7 days post–LHP injection, the maximum vessel length was observed to be 2.5±0.1 mm in the control animals (n=5), 2.0±0 mm in the 10 mg/kg A–3922 group (n=3, p<0.01 vs control), and 2.0±0.1 mm in the 30 mg/kg group(n=4, p<0.01), respectively. Twelve hours after LHP injection, VEGF was increased in the superior cornea 128.7±38.9 pg/mg wet weight in buffer control, 143.7±26.6 pg/mg wet weight in 10 mg/kg A–3922, 178.1±8.8 pg/mg wet weight in 30 mg/kg A–3922 (n=3). Conclusions: These results indicate that LHP–induced corneal NV was inhibited by pretreatment with A–3922, dihydrobenzofuran derivative. Dihydrobenzofuran derivatives may therefore be an appropriate pharmacological intervention for neovascular disorder, and its mechanisms will be discussed.Vessels growth was suppressed by A–3922 treatment.

Keywords: antioxidants • oxidation/oxidative or free radical damage 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×